To this end, potentially interested parties may communicate the Commission evidence establishing that products derived from substances listed in Annex II are not likely, under certain circumstances, to trigger adverse reactions in individuals.
Recital 3, Regulation (EU) 2024/2512
In forcesince 17 Apr 2024